Puma Biotechnology (PBYI) Total Current Liabilities (2011 - 2026)

Puma Biotechnology's Total Current Liabilities history runs 16 years deep, the most recent figure standing at $59.7 million for Q1 2026.

• Quarterly Total Current Liabilities fell 31.07% year-over-year to $59.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $59.7 million (down 31.07% YoY) and the FY2025 annual result came in at $81.3 million, down 15.46% from the prior year.
• Total Current Liabilities was $59.7 million for Q1 2026 at Puma Biotechnology, down from $81.3 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $110.4 million in Q3 2024 and bottomed at $48.2 million in Q1 2023.
• A 5-year average of $79.0 million and a median of $79.1 million in 2025 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Current Liabilities tumbled 58.79% — and 2024, when it surged 103.77%.
• Puma Biotechnology's Total Current Liabilities stood at $77.5 million in 2022, then increased by 28.26% to $99.4 million in 2023, then decreased by 3.29% to $96.1 million in 2024, then slipped by 15.46% to $81.3 million in 2025, then dropped by 26.48% to $59.7 million in 2026.
• Business Quant data shows PBYI's Total Current Liabilities at $59.7 million in Q1 2026, $81.3 million in Q4 2025, and $82.7 million in Q3 2025.